What the NDAA Means for the Future of Biotech

This episode breaks down how Congress is turning biotechnology into a core national security priority. John Stanford explains the biggest shifts in the 2025 defense bill, why China-focused guardrails are expanding, and how new investment rules could reshape biotech funding. We also cover a new bipartisan proposal to create a government-backed investment fund, and a high-stakes battle over ACA subsidies.What NDAA change do you think will impact biotech most?Should the U.S. invest directly in emerging biotechnologies?How should policymakers balance security with scientific innovation?  If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true   Timestamps:0:00 Disclaimers & Intro0:23 NDAA Overview and Why It Matters1:54 Biotech as a Strategic National Security Capability2:54 Domestic Biomanufacturing & Supply Chain Priorities3:19 DoD Bioindustrial Base & New Biotech Office4:34 Data Standardization, AI Readiness & Security5:07 Guarding the U.S. Biotech Ecosystem from China7:09 Intelligence Community’s New Biotech Role8:00 Outbound Investment Regime Explained10:12 Implications for Investors & Biotech Leaders12:42 The Independence Investment Fund Act14:37 Why Congress Wants a Government-Backed Biotech Fund14:40 Senate Showdown on ACA Subsidies & Healthcare Costs17:36 Why Access and Innovation Are Interconnected18:17 Closing Thoughts & Call for QuestionsDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.